Purchases and Sales Made in Q4 2022 in Adaptimmune Therapeutics PLC (ADAP)
This table provides information about the institutional ownership of Adaptimmune Therapeutics PLC (ADAP) during Q4 2022. The information is specifically focused on institutions that hold shares of Adaptimmune Therapeutics PLC.
| Report Date | Institution (Fund) | Operation | Option | Shares change | Value Range | Shares Held | Trade History |
|---|---|---|---|---|---|---|---|
|
Feb 13, 2023
Q4 2022
|
Gsa Capital Partners LLP
London, X0 |
SELL
|
- |
-240K- 62.97% |
$252K - $607K
|
141K
$87.5K
|
|
|
May 14, 2024
Q4 2022
|
Goldman Sachs Group Inc
New York, NY |
SELL
|
- |
-304K- 68.35% |
$320K - $770K
|
141K
$87.4K
|
|
|
Feb 13, 2023
Q4 2022
|
Goldman Sachs Group Inc
New York, NY |
SELL
|
- |
-304K- 68.35% |
$320K - $770K
|
141K
$87.4K
|
|
|
Feb 13, 2023
Q4 2022
|
Black Rock Inc.
New York, NY |
SELL
|
- |
-441K- 31.2% |
$463K - $1.12M
|
973K
$603K
|
|
|
Feb 14, 2023
Q4 2022
|
Ken Griffin
Citadel Advisors LLC | Chicago, Il
|
SELL
|
- |
-1.3M- 84.22% |
$1.36M - $3.28M
|
243K
$150K
|
|
|
Feb 14, 2023
Q4 2022
|
Pfm Health Sciences, LP
San Francisco, CA |
SELL
|
- |
-4.48M- 48.03% |
$4.7M - $11.3M
|
4.84M
$3M
|